CompletedPhase 2NCT01309997

Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease

Studying Diffuse cutaneous systemic sclerosis

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Lee, Stephanie
Principal Investigator: Stephanie Lee
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Intervention: imatinib mesylate(drug)
Enrollment: 72 enrolled
Eligibility: 2 years · All sexes
Timeline: 2011 – 2015

Study locations (10)

Mayo Clinic in Arizona, Scottsdale, Arizona, United States
Stanford University Hospitals and Clinics, Stanford, California, United States
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Washington University School of Medicine, St Louis, Missouri, United States
Roswell Park Cancer Institute, Buffalo, New York, United States
Weill Cornell Medical College, New York, New York, United States
University of North Carolina, Chapel Hill, North Carolina, United States
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
Froedtert and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States

Collaborators

National Cancer Institute (NCI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01309997 on ClinicalTrials.gov

Other trials for Diffuse cutaneous systemic sclerosis

Additional recruiting or active studies for the same condition.

See all trials for Diffuse cutaneous systemic sclerosis →

← Back to all trials